焦虑障碍心理治疗的持久效应:随访研究的荟萃分析
该荟萃分析纳入93项随机对照研究、152个心理治疗研究臂,比较惊恐障碍、广泛性焦虑障碍和社交焦虑障碍心理治疗与对照组在随访期的疗效。结果显示心理治疗获益维持至24个月,认知行为治疗随时间显著改善;药物组在停药期保持稳定,与心理治疗无显著差异;安慰剂组随访期未恶化但显著劣于认知行为治疗。结论认为心理治疗、药物及安慰剂均有持久效应,随访期效应可能受自发缓解或均值回归叠加影响。
要点
- 心理治疗获益维持至24个月,认知行为治疗随时间显著改善。
- 药物组在停药期保持稳定,与心理治疗无显著差异。
- 安慰剂组随访期未恶化,但显著劣于认知行为治疗。
核心结论
- 心理治疗、药物及安慰剂条件均显示持久效应,随访期长程效应可能被自发缓解或均值回归叠加。
研究设计与样本
- 荟萃分析纳入93项随机对照研究、152个心理治疗研究臂(认知行为治疗或其他心理治疗),涵盖惊恐障碍、广泛性焦虑障碍和社交焦虑障碍,并包含随访评估。
- 对照组包括药物组16个研究臂、药物安慰剂与心理安慰剂组共17个研究臂;计算终点及所有随访期的前后效应量并与对照组比较。
主要发现
- 心理治疗获益维持至24个月。
- 认知行为治疗随时间观察到显著改善。
- 药物组在无治疗期保持稳定,与心理治疗相比无显著差异。
- 安慰剂组随访期未恶化,但结局显著劣于认知行为治疗。
临床怎么用
- 临床可预期心理治疗(尤其认知行为治疗)在结束后的24个月内维持获益。
- 药物停药后短期内未观察到显著劣于心理治疗,应结合患者情况个体化选择。
- 解读随访期持久效应时需考虑自发缓解或均值回归的可能贡献。
局限性
- 随访期观察到的持久效应可能被自发缓解或均值回归叠加,难以完全归因于治疗本身。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is a widespread opinion that after treatment with psychotherapy, patients with anxiety disorders maintain their gains beyond the active treatment period, whereas patients treated with medication soon experience a relapse after treatment termination.AimsWe aimed to provide evidence on whether enduring effects of psychotherapy differ from control groups. METHOD: We searched 93 randomised controlled studies with 152 study arms of psychological treatment (cognitive-behavioural therapy or other psychotherapies) for panic disorder, generalised anxiety disorder and social anxiety disorder that included follow-up assessments. In a meta-analysis, pre-post effect sizes for end-point and all follow-up periods were calculated and compared with control groups (medication: n = 16 study arms; pill and psychological placebo groups: n = 17 study arms). RESULTS: Gains with psychotherapy were maintained for up to 24 months. For cognitive-behavioural therapy, we observed a significant improvement over time. However, patients in the medication group remained stable during the treatment-free period, with no significant difference when compared with psychotherapy. Patients in the placebo group did not deteriorate during follow-up, but showed significantly worse outcomes than patients in cognitive-behavioural therapy. CONCLUSIONS: Not only psychotherapy, but also medications and, to a lesser extent, placebo conditions have enduring effects. Long-lasting treatment effects observed in the follow-up period may be superimposed by effects of spontaneous remission or regression to the mean.Declaration of interestIn the past 12 months and in the near future, Dr Bandelow has been/will be on the speakers/advisory board for Hexal, Mundipharma, Lilly, Lundbeck, Pfizer and Servier. Dr Wedekind was on the speakers' board of AstraZeneca, Essex Pharma, Lundbeck and Servier. All other authors have nothing to declare.
引用
- Bandelow B, Sagebiel A, Belz M, et al. Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies. Br J Psychiatry. 2018. PMID: 29706139. doi:10.1192/bjp.2018.49
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。